,0,1,2,3,4,5,6
0,,Accession ID: NGSO-221209001,Accession ID: NGSO-221209001,Accession ID: NGSO-221209001,Accession ID: NGSO-221209001,,Page 3 of 76
1,,"Patient Name: LAN ZHENG,MEI-CHAN","Patient Name: LAN ZHENG,MEI-CHAN","Patient Name: LAN ZHENG,MEI-CHAN","Patient Name: LAN ZHENG,MEI-CHAN",,"Patient Name: LAN ZHENG,MEI-CHAN"
2,,Diagnosis: gastric cancer,Diagnosis: gastric cancer,Diagnosis: gastric cancer,Diagnosis: gastric cancer,,Diagnosis: gastric cancer
3,YOURLAB,YOURLAB,YOURLAB,YOURLAB,YOURLAB,YOURLAB,YOURLAB
4,,,,Approved Therapies,Approved Therapies,,Approved Therapies
5,,,,,Associated With,Clinical,Clinical
6,Gene/Variant,Allelic Fraction,Gastric Cancer,Other Indications,Resistance,Trials,Trials
7,MRE11,50.0% (of 229,50.0% (of 229,50.0% (of 229,50.0% (of 229,2,2
8,c.689C>T,reads),reads),reads),reads),reads),reads)
9,p.P230L,p.P230L,p.P230L,p.P230L,p.P230L,p.P230L,p.P230L
10,g.94471730G>A,g.94471730G>A,g.94471730G>A,g.94471730G>A,g.94471730G>A,,g.94471730G>A
11,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C
12,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,,Likely Pathogenic
13,POLE,2.88% (of 139 reads),trifluridine,cladribine,cladribine,cladribine,cladribine
14,p.V1446fs*3,p.V1446fs*3,p.V1446fs*3,p.V1446fs*3,p.V1446fs*3,clofarabine,p.V1446fs*3
15,g.132643513_132643,g.132643513_132643,g.132643513_132643,cytarabine,cytarabine,cytarabine,cytarabine
16,514de|CA,Tier 2C,Tier 2C,Tier 2C,Tier 2C,daunorubicin,Tier 2C
17,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C
18,Pathogenic,Pathogenic,Pathogenic,Pathogenic,Pathogenic,Pathogenic,Pathogenic
19,RNF43,7.71% (of 441 reads),7.71% (of 441 reads),7.71% (of 441 reads),7.71% (of 441 reads),RNF43,7.71% (of 441 reads)
20,c.813_825de|GTGTG,c.813_825de|GTGTG,c.813_825de|GTGTG,c.813_825de|GTGTG,c.813_825de|GTGTG,,c.813_825de|GTGTG
21,CCATCTGT,CCATCTGT,CCATCTGT,CCATCTGT,CCATCTGT,CCATCTGT,CCATCTGT
22,p.C272fs*143,p.C272fs*143,p.C272fs*143,p.C272fs*143,p.C272fs*143,p.C272fs*143,p.C272fs*143
23,g.58360807_583608,g.58360807_583608,g.58360807_583608,g.58360807_583608,g.58360807_583608,,g.58360807_583608
24,19delACAGATGGCA,19delACAGATGGCA,19delACAGATGGCA,19delACAGATGGCA,19delACAGATGGCA,,19delACAGATGGCA
25,CAC,CAC,CAC,CAC,CAC,CAC,CAC
26,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C,Tier 2C
27,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,Likely Pathogenic,,Likely Pathogenic
28,TP53,8.13%(of246 reads),8.13%(of246 reads),acalabrutinib,chlorambucil,2,2
29,c.743G>A,c.743G>A,c.743G>A,acalabrutinib,fludarabine,c.743G>A,fludarabine
30,p.R248Q,p.R248Q,p.R248Q,/obinutuzumab,/obinutuzumab,p.R248Q,/obinutuzumab
31,g.7674220C>T,g.7674220C>T,g.7674220C>T,g.7674220C>T,lenalidomide,,lenalidomide
32,Tier 2C,Tier 2C,Tier 2C,alemtuzumab,rituximab,rituximab,rituximab
33,Pathogenic,Pathogenic,Pathogenic,alemtuzumab,alemtuzumab,Pathogenic,alemtuzumab
34,,,,/rituximab,/rituximab,/rituximab,/rituximab
35,,,,bortezomib,bortezomib,bortezomib,bortezomib
36,,,,/rituximab,/rituximab,/rituximab,/rituximab
37,,,,decitabine,decitabine,decitabine,decitabine
38,,,,duvelisib,duvelisib,duvelisib,duvelisib
39,,,,fludarabine,fludarabine,fludarabine,fludarabine
40,,,,phosphate,phosphate,phosphate,phosphate
41,,,,ibrutinib,ibrutinib,ibrutinib,ibrutinib
42,,,,idelalisib,idelalisib,idelalisib,idelalisib
43,,,,idelalisib,idelalisib,idelalisib,idelalisib
44,,,,/rituximab,/rituximab,/rituximab,/rituximab
45,,,,lenalidomide,lenalidomide,lenalidomide,lenalidomide
